SG Americas Securities LLC Acquires 5,412 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)

SG Americas Securities LLC raised its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSMGet Rating) by 64.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 13,862 shares of the company’s stock after purchasing an additional 5,412 shares during the quarter. SG Americas Securities LLC’s holdings in Axsome Therapeutics were worth $619,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the business. State of New Jersey Common Pension Fund D bought a new stake in shares of Axsome Therapeutics during the third quarter worth $1,562,000. WCM Investment Management LLC lifted its position in shares of Axsome Therapeutics by 3.9% during the third quarter. WCM Investment Management LLC now owns 133,705 shares of the company’s stock worth $5,903,000 after purchasing an additional 5,028 shares during the last quarter. Moody Aldrich Partners LLC lifted its position in shares of Axsome Therapeutics by 187.4% during the third quarter. Moody Aldrich Partners LLC now owns 122,261 shares of the company’s stock worth $5,455,000 after purchasing an additional 79,721 shares during the last quarter. Amundi purchased a new position in shares of Axsome Therapeutics during the second quarter valued at $135,000. Finally, Legal & General Group Plc increased its stake in shares of Axsome Therapeutics by 26.6% during the second quarter. Legal & General Group Plc now owns 28,532 shares of the company’s stock valued at $1,093,000 after buying an additional 5,987 shares during the period. 59.71% of the stock is currently owned by institutional investors.

Axsome Therapeutics Price Performance

Shares of NASDAQ AXSM opened at $70.83 on Monday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 4.15 and a current ratio of 4.19. The company has a market cap of $3.08 billion, a PE ratio of -17.45 and a beta of 1.83. The business has a 50-day simple moving average of $69.54 and a two-hundred day simple moving average of $56.75. Axsome Therapeutics, Inc. has a fifty-two week low of $20.63 and a fifty-two week high of $82.00.

Axsome Therapeutics (NASDAQ:AXSMGet Rating) last issued its quarterly earnings results on Monday, November 7th. The company reported ($1.03) earnings per share for the quarter, topping the consensus estimate of ($1.10) by $0.07. The business had revenue of $16.85 million during the quarter, compared to analyst estimates of $16.59 million. As a group, equities analysts expect that Axsome Therapeutics, Inc. will post -4.42 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

AXSM has been the topic of several research reports. Loop Capital initiated coverage on Axsome Therapeutics in a research note on Tuesday, November 1st. They set a “buy” rating and a $95.00 price target on the stock. Guggenheim raised their price target on Axsome Therapeutics from $72.00 to $80.00 and gave the company a “buy” rating in a research note on Friday, November 11th. Cantor Fitzgerald raised their price target on Axsome Therapeutics from $88.00 to $96.00 in a research note on Tuesday, November 8th. Mizuho restated a “buy” rating and set a $80.00 price target on shares of Axsome Therapeutics in a research note on Monday, November 28th. Finally, Cowen cut their price target on Axsome Therapeutics to $125.00 in a research note on Wednesday, October 5th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $107.69.

Axsome Therapeutics Profile

(Get Rating)

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation.

Further Reading

Want to see what other hedge funds are holding AXSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axsome Therapeutics, Inc. (NASDAQ:AXSMGet Rating).

Institutional Ownership by Quarter for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.